AbbVie's Rinvoq Shows Continued Repigmentation in Patients with Non-Segmental Vitiligo Through Week 76
Phase 3 trials demonstrated that AbbVie’s (ABBV) Rinvoq, an oral Janus kinase inhibitor, continued to show improvement in repigmentation for patients suffering from non-segmental vitiligo through week 76. The Viti-Up-1 study reported that at the 76-week mark, 55.1% of participants experienced significant facial and total body repigmentation. These findings reinforce Rinvoq’s potential as a long-term treatment option for non-segmental vitiligo patients who have limited therapeutic choices. The results could support regulatory or commercial expansion efforts by AbbVie in the dermatology space, potentially enhancing its market position with this drug across multiple indications.
Tickers: $ABBV
Topics: AbbVie clinical trials Rinvoq vitiligo